Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Name:
PIIS0959804917313692.pdf
Size:
1.113Mb
Format:
PDF
Description:
Open access full text article
Authors
Valpione, SaraGremel, Gabriela
Mundra, P A
Middlehurst, P
Galvani, Elena
Girotti, Maria Romina
Lee, Rebecca J
Garner, G
Dhomen, Nathalie
Lorigan, Paul C
Marais, Richard
Affiliation
Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UKIssue Date
2017-11-23
Metadata
Show full item recordAbstract
Tumour burden is a prognostic biomarker in metastatic melanoma. However, tumour burden is difficult to measure and there are currently no reliable surrogate biomarkers to easily and reliably determine it. The aim of this study was to assess the potential of plasma total cell free DNA as biomarker of tumour burden and prognosis in metastatic melanoma patients.Citation
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. 2017, 88:1-9 Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2017.10.029PubMed ID
29175734Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2017.10.029
Scopus Count
Collections
Related articles
- Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma cfDNA, LDH, VEGF, PD-L1, and IFN-γ Measurements.
- Authors: Ita MI, Wang JH, Heffron CC, Power DG, Nolan Y, Toulouse A, Lim CCH, Fanning N, Redmond HP
- Issue date: 2022 Feb
- Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
- Authors: Xu X, Yu Y, Shen M, Liu M, Wu S, Liang L, Huang F, Zhang C, Guo W, Liu T
- Issue date: 2020 Oct 16
- Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
- Authors: Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Macé S, de Bono JS
- Issue date: 2018 Sep
- Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
- Authors: Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG
- Issue date: 2019 Jul 1
- Comprehensive characterization of circulating tumor cells and cell-free DNA in patients with metastatic melanoma.
- Authors: Bos MK, Kraan J, Starmans MPA, Helmijr JCA, Verschoor N, De Jonge MJA, Joosse A, van der Veldt AAM, Te Boekhorst PAW, Martens JWM, Sleijfer S, Wilting SM
- Issue date: 2024 Nov